Seoul: SK Biopharmaceuticals Co. said Thursday that its fourth-quarter net income surged more than twentyfold from a year earlier to 186.4 billion won (US$129 million). In a regulatory filing, the company reported an operating profit of 40.7 billion won for the quarter, up from 14.8 billion won a year ago. Revenue climbed 28.6 percent to 163 billion won.
According to Yonhap News Agency, the operating profit exceeded market expectations by 33.7 percent, based on a survey by Yonhap Infomax, the financial data unit of Yonhap News Agency. A consensus estimate for net profit was not available.